Key facts
- Essentia BioSciences’s last known valuation is $7.4M (Mar 2022).
- It has raised $15.8M; the latest was Early Stage VC ($14.2M) in Jan 2026.
- Notable investors include YuanBio Venture Capital, Peiyang Begonia Fund, Tianjin Venture Capital, Qingdao Haier Venture Capital, AlphaMol — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Essentia BioSciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Essentia BioSciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Essentia BioSciences
Provider of biotechnology services intended to support advanced cell and gene therapy development. The company offers specialized capabilities, including cell characterization, identity verification, genetic stability assessment, and contaminant detection across critical stages of biopharmaceutical research and manufacturing, enabling patients with effective pancreatic islet treatments.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2021
- Website
- essentiabiosciences.com/
- Ownership
- Privately Held (backing)
Essentia BioSciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Essentia BioSciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Essentia BioSciences in its N-PORT filings yet. We sweep new filings monthly.